Marker system, in particular for baculovirus-expressed subunit antigens
AssigneeBoehringer Ingelheim Vetmedica GmbH
InventorsArun V. Iyer, Joseph Ralph Hermann, Michael B. Roof, Eric Martin Vaughn, Merrill Lynn Schaeffer
Life of this patent
Estimating the term…
Abstract
The present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a method of determining whether an individual has received an immunogenic composition comprising a recombinant protein produced by a baculovirus expression system in cultured insect cells.
Claims21
A method of differentiating a non-vaccinated mammal or bird from a mammal or bird which has received an immunogenic composition comprising the steps of:
- a. obtaining a biological sample from a mammal or bird;
- b. contacting antibodies of the biological sample with a capture reagent, wherein the capture reagent specifically binds antibodies specific for a rhabdovirus antigen and is selected from:
- i. a polypeptide comprising a sequence having at least 95% sequence identity with any one of SEQ ID NOs:
- 1 to 8;
- ii. a RNA virus which comprises a polypeptide comprising an amino acid sequence having at least 95% sequence identity with the sequence of SEQ ID NO:
- 1 and/or SEQ ID NO:
- 7;
- and
- iii. a synthetic polypeptide having a sequence selected from the sequences consisting of 5 to 11 consecutive amino residues of SEQ ID NO:
- 1 or SEQ ID NO:
- 7;
- and
- c. detecting for the presence of capture reagent-antibody complexes,
- wherein the presence of capture reagent-antibody complexes indicates that said mammal or bird has received said immunogenic composition, and thus differentiates a vaccinated mammal or bird from a non-vaccinated mammal or bird.
A kit for differentiating a non-vaccinated mammal or bird from a mammal or bird which has received an immunogenic composition, comprising a capture reagent immobilized to a solid support, wherein the capture reagent specifically binds antibodies specific for a rhabdovirus antigen and is selected from:
- a. a recombinant polypeptide comprising a sequence having at least 95% sequence identity with any one of SEQ ID NOs:
- 1 to8;
- b. a RNA virus which comprises a polypeptide comprising an amino acid sequence having at least 95% sequence identity with the sequence of SEQ ID NO:1 and/or SEQ ID NO:7;
- and
- c. polypeptide fragments consisting of 5 to 100 consecutive amino acid residues of SEQ ID NO:1 or SEQ ID NO:7.
Dependencies are inferred from the claim text.